Pamela K. Woodard1, Matthew R. Lyons2, Cylen Javidan-Nejad1, Ibrahim M. Saeed3, Donna Lesniak4, Gary McNeal5, Agus Priatna5, Sven Zuehlsdorff6, Robert J. Gropler1
1Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, United States; 2Cardiology, Case Western School of Medicine, Cleveland, OH, United States; 3Cardiology, Saint Lukes Hospital, Kansas City, MO, United States; 4Mallinckrodt Institute of Radiology, Washington University School of Medicine, St., Louis, MO, United States; 5Siemens Medical Systems, Malvern, PA, United States; 6Siemens Medical Systems, Erlangen, Germany
Cardiac stress MR perfusion imaging requires an MRI compatible infusion pump for the administration of adenosine or a non-MRI compatible pump housed in the control room or beyond the 10-Gauss line. This later method requires high-pressure extension tubing running for some distance across the control room and/or scan room floor. This has the potential to compromise both the quality of the examination and patient safety. Regadenoson is a recently FDA-approved A2A receptor agonist which can be given intravenously in a single 400 microgram bolus. We hypothesize that a single injection of regadenoson could be used instead of an adenosine infusion to produce coronary vasodilatation and demonstrate myocardial ischemia during first-pass perfusion cardiac MRI. Forty-four patient were imaged. All but one patient tolerated the regadenoson cardiac MR perfusion examination. Regadenoson can be used safely in cardiac MR perfusion imaging to demonstrate ischemia.